The beat-and-raise quarter with accelerating subscription growth and strong AI product momentum (Falcon, Vault AI) supports a bullish thesis. Traders should watch for continued top-20 biopharma wins and Falcon go-lives in H2 as catalysts. The raised guidance provides a clear upward earnings trajectory, making VEEV attractive for long positions ahead of the Q3 report.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $282.13entry
- T+1 · 3mo ago −1.93%α −1.70% · $276.69
- T+5 · 3mo ago +0.80%α +0.53% · $284.38
- T+20 · 8w ago −1.33%α −1.22% · $278.39
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Veeva Systems reported fiscal Q2 2027 results that exceeded guidance on all metrics, with total revenue of $928.0M (+18% YoY) and non-GAAP EPS of $2.35, beating the $2.22 consensus by 5.9%. The company raised its full-year revenue guidance to $3.682-$3.687B and non-GAAP EPS to ~$9.21, signaling accelerating momentum in its core life sciences cloud business, particularly Vault CRM and the new Falcon AI platform. The strong beat and raised guidance are a clear bullish signal for the stock, supported by robust subscription revenue growth and operating leverage.
Key Financial Metrics
Key Facts
- Total revenues of $928.0M, up 18% YoY, above consensus of $905.3M.
- Non-GAAP diluted EPS of $2.35, beating consensus of $2.22 by 5.9%.
- Subscription revenues of $766.8M, up 16% YoY, driven by Vault CRM and R&D/Quality Solutions.
- Operating income of $275.0M (GAAP) and $415.9M (non-GAAP), up 40% and 18% YoY respectively.
- Raised full-year FY2027 guidance: revenue to $3.682-$3.687B and non-GAAP EPS to ~$9.21.
- Vault CRM secured 5 top-20 biopharma wins in the quarter, with 12 total top-20 commitments globally.
- Veeva Falcon AI platform launched with 5 early adopters, on track for initial go-lives this year.
- Operating cash flow of $238.7M for the quarter, up from $238.4M YoY.
- Repurchased $472.7M of common stock in H1 FY2027.
Financial Impact
Revenue beat of $22.7M (+2.5% vs consensus) and EPS beat of $0.13 (+5.9% vs consensus). Full-year guidance raised by ~$30M at midpoint.
Risk Factors
- Guidance assumes continued execution; any slowdown in top-20 biopharma adoption could disappoint.
- AI product ramp (Falcon) is early-stage; go-live delays or adoption misses could weigh on sentiment.
- Stock-based compensation remains elevated at $136.8M for the quarter, diluting GAAP earnings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302860933 |
Track record
10 reports on VEEV
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +54.98% at T+60 after the Jun 3, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $303.73 to $301.53 Now $299.28 −1.47% ▼ −0.72% −3.32% vs SPY
- Oct 22, 202624d ago Institutional Cluster Bearish 4/10 Entry $323.04 to $312.96 Now $299.28 +7.36% ▲ +3.12% +2.56% vs SPY
- Oct 14, 20264w ago 144 Neutral 2/10 Entry $313.03 to $322.55 Now $299.28 −4.39% ▲ +3.04% +4.06% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $270.75 to $285.45 Now $299.28 +10.54% ▲ +5.43% +6.10% vs SPY
- Sep 16, 20268w ago Insider Cluster Neutral 3/10 Entry $263.75 to $274.84 Now $299.28 +13.47% ▲ +4.20% +3.35% vs SPY
- Aug 26, 202611w ago Press Release Bullish 7/10 Viewing Entry $282.13 to $284.38 Now $299.28 +6.08% ▲ +0.80% +0.53% vs SPY
- Jun 3, 202623w ago 8-K Bullish 7/10 Entry $178.54 to $161.55 Now $299.28 +67.63% ▼ −9.51% −6.96% vs SPY
- May 4, 202628w ago DEFA14A Neutral 3/10 Entry $170.18 to $159.30 Now $299.28 +75.86% ▼ −6.39% −9.33% vs SPY
- Apr 20, 202630w ago 8-K Neutral 3/10 Entry $167.71 to $158.38 Now $299.28 +78.45% ▼ −5.56% −6.65% vs SPY
- Mar 4, 202636w ago 8-K Bullish 8/10 Entry $195.27 to $180.48 Now $299.28 +53.27% ▼ −7.57% −5.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers